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Bretagne Occidentale, Brest, France, 5 Wellcome Trust Clinical Research Facility, Western General
Hospital, Edinburgh, Scotland, United Kingdom, 6 Centre for Clinical Brain Sciences, University of Edinburgh,
Edinburgh, Scotland, United Kingdom, 7 Division of Hematology, Department of Medicine, University of
Ottawa, Ottawa, Canada
* vyogendrakumar@toh.ca
Abstract
Introduction
To summarize and compare the effectiveness of pharmacological thromboprophylaxis to
pneumatic compression devices (PCD) for the prevention of venous thromboembolism in
patients with acute intracerebral hemorrhage.
Methods
MEDLINE, PUBMED, EMBASE, and CENTRAL were systematically searched to identify
randomized and non-randomized studies that compared each intervention directly to each
other or against a common control (hydration, anti-platelet agents, stockings) in adults with
acute spontaneous intracerebral hemorrhage. Two investigators independently screened
the studies, extracted data, and appraised risk of bias. Studies with a high risk of bias were
excluded from our final analysis. The primary outcome was the occurrence of venous throm-
boembolism (proximal deep vein thrombosis or pulmonary embolism) in the first 30 days.
Results
8,739 articles were screened; four articles, all randomized control trials, met eligibility crite-
ria. Bayesian network meta-analysis was performed to calculate risk estimates using both
fixed and random effects analyses. 607 patients were included in the network analysis. PCD
were associated with a significant decrease in venous thromboembolism compared to con-
trol (OR: 0.43, 95% Credible Limits [CrI]: 0.23–0.80). We did not find evidence of statistically
significant differences between pharmacological thromboprophylaxis and control (OR: 0.93,
95% CrI: 0.19–4.37) or between PCD and pharmacological thromboprophylaxis (OR: 0.47,
95% CrI: 0.09–2.54).
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Conclusion
PCDs are superior to control interventions, but meaningful comparisons with pharmacother-
apy are not possible due to a lack of data. This requires further exploration via large prag-
matic clinical trials
Trial registration
PROSPERO: CRD42018090960
Introduction
Venous thromboembolism is a common complication for patients suffering from a spontane-
ous intracerebral hemorrhage (ICH) [1,2]. The two primary methods of VTE prevention in
use today are mechanical compression and pharmacological thromboprophylaxis.
Mechanical prevention, in the form of compression stockings and hoses, graduated com-
pression stockings, and pneumatic compression devices (PCD) have been used to varying
degrees in clinical practice. Of the three, PCD have emerged as the most effective in VTE pre-
vention [3], with the two former devices no longer recommended as first line therapy by inter-
national guidelines [4–7]. The use of PCD in the context of ICH is increasing in clinical
practice [8]. However, trials displaying its effectiveness are limited and throughout the litera-
ture are concerns regarding compliance and cost [9,10].
While commonly used to prevent VTE in a variety of medical scenarios [11], the use of
pharmacological thromboprophylaxis in ICH is an area of ongoing debate. The primary con-
cern is that these medications may exacerbate intracranial bleeding but this has not been dem-
onstrated in observational studies [1,12].
In this study, we sought to compare the effectiveness of each intervention indirectly
through the use of network meta-analysis, which can inform comparisons between interven-
tions based upon all available direct and indirect evidence [13].
Methods
Protocol and registration
The protocol for this study was registered with PROSPERO (CRD42018090960) and published
[14]. This study was conducted using recommendations from the Cochrane Handbook for
Systematic Reviews, and findings were prepared with guidance from the PRISMA extension
statement for network meta-analysis [15]. The authors declare that all supporting data are
available within the article and online-only supplement. As new patient data was not collected
for this study, local research ethics board approval was not required.
Eligibility criteria
Included studies were randomized controlled trials or non-randomized studies with a control
group that enrolled adults (� 18 years) with acute spontaneous ICH who were treated with
PCD or pharmacological therapy. Studies exclusively focused on subarachnoid or subdural
hemorrhage, or traumatic etiologies were excluded. Studies that involved a mixed population
(e.g. intensive care unit population) of patients were included if ICH patients were assessed
separately within the study publication.
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All studies investigating short-term pharmacotherapy were considered. No restrictions on
dose, frequency, duration, or route of administration were used. We limited our inclusion to
devices that provided PCDs only. We had no restrictions on whole leg vs. calf-only compres-
sion. Control populations were defined as those who did not receive PCD of pharmacological
prophylaxis. These populations may receive intravenous hydration, antiplatelets, compression/
graduated stockings, or any combination of the aforementioned.
Information sources and trial search
We conducted a comprehensive search of MEDLINE, EMBASE, PubMed, and CENTRAL
from inception until March 1st, 2018, as per our protocol, and performed an updated search
from March 1st, 2018 to May 6th, 2020 via MEDLINE and EMBASE. A sample search strategy
is available in S1 Table. Electronic searches were supplemented by hand searching of reference
lists of relevant articles and reviews. Details of ongoing studies were sought through review of
ClinicalTrials.Gov. There was no restriction on study locations. We restricted our inclusion
criteria to studies only in the English language.
Study selection and data collection
Two independent reviewers performed title, abstracts, full text screening, and data extraction.
Data collection was performed using a standardized data collection form. We collected infor-
mation regarding study design and enrollment criteria, baseline patient characteristics, and
details of the intervention/comparator groups used in each study. Baseline patient characteris-
tics included details on age, sex, background medical history, hemorrhage volume, start time
of intervention, and clinical severity. Detailed outcome data on DVT and pulmonary embo-
lism (PE) occurrence (asymptomatic/symptomatic, proximal/distal) was collected wherever
possible. The primary outcome of interest was VTE, defined as the development of a proximal
DVT (symptomatic or asymptomatic) or PE, diagnosed within the first 30 days of hemorrhage
onset. The secondary outcome was the occurrence of any DVT (proximal or distal) or PE
within the first thirty days. Safety data and treatment dropouts were reported where available.
Risk of bias in individual studies
Two reviewers independently assessed the risk of bias of randomized controlled trials and
non-randomized observational studies using the Cochrane Collaboration tool and the Robins-
I, respectively [16,17]. Results were summarized in tabular format and to reduce the risk of
bias in our final effect estimates, studies that scored “high risk” on a number of categories
within the Cochrane risk of bias tool or “Critical/Serious” on the overall score of the Robins-I
tool were excluded from our primary analysis.
Data synthesis (Summary measures, synthesis of results)
We assessed baseline patient characteristics and event rates of the comparator arms to ensure
that exchangeability assumptions were met and that there would be enough similarity between
the included studies to allow for reliable data pooling [18]. We utilized an aggregate level
Bayesian network meta-analyses to derive estimates of comparative effectiveness of each inter-
vention relative to others in the treatment network. We calculated direct effect estimates
between each intervention against a control. An indirect effect estimate was then calculated
comparing the two interventions to each other using the control arm as a common compara-
tor. Both outcomes of interest were reported in terms of dichotomous data, and findings from
network-meta analyses were reported in terms of odds ratios (OR) with corresponding 95%
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credible intervals (CrIs). We performed all analyses using three chains of initial values, with
totals of 50,000 or more burn-in and sampling iterations. Adequacy of model fit was assessed
by comparing the posterior total residual deviance to the number of unconstrained data points
in each analysis, and comparisons between models (for example, fixed versus random effects
models) was based upon the deviance information criterion (DIC) (with differences of 5 points
or more indicating an important difference). As neither of the networks studied included a
closed loop, no checks for inconsistency of direct and indirect evidence were performed. We
used the I2 statistic generated from traditional pairwise meta-analyses for each piece of the
treatment network to assess statistical heterogeneity. We performed all analysis using RevMan
5.3 (Cochrane, London, UK), WinBUGS version 1.4.4 (MRC Biostatistics Unit, Cambridge,
UK) and NetMetaXL packages [19].
Risk of bias across studies and additional analyses
We compared all randomized controlled trials to protocols that had been previously published,
if available. Pre-determined outcomes in the methodology were compared to the outcomes
presented in the results section of each study report to monitor for changes in outcome priori-
tization and selective reporting. Funnel plots were planned to be assessed visually for indica-
tions of publication bias when 10 or more studies were available. We judged the quality of
evidence for all outcomes using a framework developed by the GRADE working group specifi-
cally designed for randomized and non-randomized studies in the context of a network meta-
analysis [20].
Results
Study selection
Among 11,733 records retrieved by the literature search, there were 8,739 left for review after
removal of duplicates across databases. Of these, 8,712 were excluded after screening of titles
and abstracts, leaving 27 for full-text screening. Full-text screening resulted in exclusion of 19
studies (S2 Table). Eight studies, consisting of four randomized controlled trials and four non-
randomized studies, were retained for inclusion in the review (Fig 1). The four non-random-
ized studies all scored severe/critical for overall risk of bias and were therefore excluded from
primary analysis.
Risk of bias within studies
Risk of bias assessments are summarized in S1 Fig and S3 Table. Risk of bias assessment
deemed all RCTs appropriate for inclusion in the network meta-analysis. All four non-ran-
domized studies scored highly for concerns of confounding and were deemed to possess a
high risk of bias.
Study characteristics
Of the four randomized controlled trials included in our analysis, one study focused on phar-
macological treatment [21] and three focused on PCD [22–24]. Details of each study are
included in Tables 1 and 2.
Orken et al. (2009) [21] was a single center randomized controlled trial where 75 patients
with ICH were randomized to enoxaparin 40 mg versus compression stockings (control), 48
hours after stroke onset. Total duration of treatment was 21 days. Screening ultrasound and
CT pulmonary angiography (CTPA) were performed on day 7. Repeat imaging was performed
if patients were symptomatic from days 8–21. Lower extremity veins included the iliac,
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femoral, long saphenous, popliteal, and paired calf veins. For CTPA, any filling defects in the
pulmonary arteries were interpreted as embolism. All radiological endpoints were evaluated in
a blinded fashion. There were no treatment dropouts or complications reported by the investi-
gators. Follow-up neuroimaging was performed at days 3, 7, and 21. Hematoma expansion
was not observed in either treatment group.
The Venous Intermittent Compression and Thrombosis Occurrence Related to Intra-cere-
bral Acute hemorrhage study (VICTORIAh; 2005) [24] randomized patients with traumatic or
spontaneous ICH to PCD or elastic stockings (control) at a single center. We were able to
Fig 1. Literature search and study selection flow diagram.
https://doi.org/10.1371/journal.pone.0234957.g001
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contact study authors to acquire summary outcome data on spontaneous ICH patients
(n = 118). Patients were randomized within the first 48 hours of hospital admission and
screening compression ultrasound was performed on day 10 by investigators blinded to treat-
ment allocation. Day 10 screening ultrasound was used to determine the presence of asymp-
tomatic lower limb DVT. Patients with symptoms of DVT at any time up to day 30 were
evaluated by ultrasound. PE was diagnosed by high probability ventilation perfusion lung scan
or CTPA, based on clinical suspicion from the treating physician. Information on hematoma
expansion was not reported. Nine patients (17%) discontinued PCD therapy within the first 10
days due to lack of tolerance. Potential complications with PCDs was not reported.
The Compression pneumatique Intermittente en reanimation (CIREA1; 2013) [23] study
was a multicenter, prospective, open label, blinded endpoint, randomized controlled trial com-
paring PCDs to graduation compression stockings (control) in intensive care unit patients
within 48 hours of admission to the intensive care unit. Study authors were contacted to
acquire summary outcome data on spontaneous ICH patients only (n = 100). Day 6 screening
ultrasound was used to determine the presence of asymptomatic lower limb DVT. Patients
with symptoms of DVT at any time up to day 30 were evaluated by ultrasound. Anticoagula-
tion was contraindicated during the first six days of the study. Symptomatic PE within the first
30 days was assessed by CTPA based on clinical suspicion. Information on hematoma expan-
sion was not reported. Two patients (3.6%) discontinued therapy due to lack of tolerance.
PCD associated complications was not reported.
Table 1. Details of included studies (Pharmacological prophylaxis).
Study Prevention of Deep Venous Thrombosis and
Pulmonary Embolism in Patients With Acute
Intracerebral Hemorrhage (Orken et al.[21])
Year of Publication 2009
Country(ies) of Study Turkey
Study Type Randomized Controlled Trial
Total Number of Patients 75
Patient Characteristics Intervention Control
# of Patients 39 36
Age (mean, SD) 68.1 (11.98) 66.08 (9.6)
Male (n, %) 17 (43.6%) 28 (77.8%)
Hypertension 32 (82.1%) 29 (80.6%)
Prior Stroke /TIA 11 (28.2%) 6 (16.7%)
Alcohol Abuse 1 (2.6%) 3 (8.3%)
National Institute of Health Stroke Scale (mean, SD) 9.74 (6.06) 8.61 (6.87)
Location (n, %)
Lobar (Subcortex) 11 (28.21%) 8 (22.22%)
Non-Lobar 28 (71.79%) 28 (77.78%)
Agent Used (Generic Name) Enoxaparin Sodium Long CS
Dose 40 mg NA
Start Time from Hemorrhage Onset 48 Hours 48 Hours
Frequency of Dosing Once Daily NA
Route of Administration Subcutaneous NA
Duration of Treatment 21 days 21 days
VTE Events 4 (4 DVT, 0 PE) 4 (3 DVT, 1 PE)
Abbreviations: DVT = Deep vein thrombosis; ES = elastic stockings; CS = compression stockings; PCD = pneumatic
compression device; PE = pulmonary embolism; NA = not applicable; NR = not recorded; SD = standard deviation
https://doi.org/10.1371/journal.pone.0234957.t001
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The Clots in Legs Or sTockings after Stroke (CLOTS3; 2013) [22] study was a multicenter
trial in which immobilized acute stroke (ischemic or hemorrhagic) patients were randomized
to PCDs plus standard care (which may include IV hydration, graduated compression stock-
ings, antiplatelets, and anticoagulants) versus standard care alone. Patients were randomized
within day 0–3 of stroke onset and screening compression ultrasound was performed on
days 7–10 and days 25–30. The primary outcome was symptomatic or asymptomatic DVT
in the popliteal or femoral (proximal) veins detected on a screening ultrasound or any symp-
tomatic DVT in the popliteal or femoral veins, confirmed by imaging, within 30 days of
Table 2. Details of included studies (Pneumatic compression devices).
Study: Prevention of Venous Thrombosis in
Patients with Acute Intracerebral
Hemorrhage (VICTORIAh)[24]
Intermittent pneumatic compression to
prevent venous thromboembolism in
patients with high risk of bleeding
hospitalized in intensive care units: the
CIREA1 randomized trial[23]
Effectiveness of intermittent pneumatic
compression in reduction of risk of deep vein
thrombosis in patients who have had a stroke
(CLOTS 3): a multicentre randomized
controlled trial[22]
Year of Publication 2005 2013 2013
Country(ies) of Study France France United Kingdom
Study Type Randomized Controlled Trial Randomized Controlled Trial Randomized Controlled Trial
Total Number of
Patients
118 100 314
Patient
Characteristics
Intervention Control Intervention Control Intervention Control
Number of Patients 53 65 56 44 156 158
Age (mean, SD) 63.2 (12.9) 67 (11.2) 57.6 (14.5) 56.4 (15.1) 72.4 (12.8) 72.8 (11.8)
Male (n, %) 32 (60.4) 35 (53.8) 30 (53.6) 27 (61.4) 84 (53.8%) 67 (57.6%)
Hypertension (n, %) 21 (39.6%) 34 (52.3%) NR NR NR NR
Cancer (n, %) 7 (13.2%) 1 (1.5%) 3 (5.4%) 2 (4.5%) NR NR
Antiplatelet Use (n,
%)
9 (17%) 16 (24.6%) 7 (12.5%) 7 (15.9%) 7 (4.5%) 10 (6.3%)
Alcohol Abuse (n, %) 9 (24.5%) 13 (20.0%) NR NR NR NR
Glasgow coma scale
(mean, SD)
9.5 (4.6) 9.4 (4.5) NR NR NR NR
Immobile (n, %)� NR NR NR NR 156 (100%) 158 (100%)
Neurosurgical
Intervention (n, %)
14 (26.4%) 15 (23.0%) 16 (28.6%) 12 (27.3%) NR NR
Device Used PCD + ES ES PCD + GCS GCS PCD ES
Start Time from
Hemorrhage Onset
<48 Hours <48 Hours <36 hours^ <36 hours� Day 0–3 Day 0–3
Location: Knee/Thigh Thigh-length NA Thigh-length NA Thigh-length NA
Target Treatment
Duration
10 Days 10 Days 6 Days 6 Days 30 Days 30 Days
Duration of
Treatment (mean, SD)
8.5 (0.8) 8.5 (1.1) 5.9 (1.7) 6.1 (1.4) 15.0 (10.7) NA
Treatment Dropouts
(n,%)
9 (17%) 1 (1.5%) 2 (3.6%) 0 (0%) 2 (0.01%) 1 (0.003%)
VTE Events 4 (3 Distal DVT, 0
Proximal DVT, 1 PE)
11 (8 Distal DVT, 3
Proximal DVT, 0
PE)
4 (2 Distal DVT, 1
Proximal DVT, 1 PE)
6 (3 Distal DVT, 3
Proximal DVT, 0
PE)
34 (20 Distal DVT, 10
Proximal DVT, 4 PE)
46 (17 Distal DVT,
26 Proximal DVT, 3
PE)
�defined specifically by the CLOTS3 trialists as an inability to mobilize without help to the toilet
^within 36 hours of admission to ICU
Abbreviations: DVT = Deep vein thrombosis; ES = elastic stockings; GCS = graduated compression stockings; PCD = pneumatic compression device; PE = pulmonary
embolism; NA = not applicable; NR = not recorded; SD = standard deviation
https://doi.org/10.1371/journal.pone.0234957.t002
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randomization. Diagnosis of PE in the first 30 days was confirmed by CTPA or ventilation–
perfusion (VQ) lung scan. Information on hematoma expansion was not reported. Data on
hemorrhage characteristics was not collected. ICH patients (n = 376) were included in this
study and individual patient data was acquired from study authors. The following patients
were excluded: patients who were using anticoagulation prior to randomization (n = 4) or
were started on anticoagulation following randomization for atrial fibrillation or an artificial
heart valve (n = 4), and patients with missing outcome data or who died within the first 30
days (n = 54). PE was not identified as a cause of death within the first thirty days (S4 Table).
Three-hundred and fourteen patients were included in our primary analysis. No skin breaks
were observed in either treatment group.
Patient information from each study was compared and discussed. We judged that the
exchangeability assumption for network meta-analysis was met and proceeded with our net-
work meta-analyses.
Synthesis of results
Head-to-head comparisons between pharmacotherapy and PCD from the included studies are
depicted in the network plot seen in Fig 2. The overall incidence of VTE (proximal asymptom-
atic or symptomatic DVT, PE) was 9.9% (Tables 1 and 2). Assessment of measures of model fit
(S5 Table) suggested reasonable fit of both the fixed effects (FE) and random effects (RE) mod-
els and DIC estimates were similar. Direct and indirect comparisons are summarized in Fig 3.
Findings from the FE analysis suggested that PCDs are associated with a significantly
decreased odds of venous thromboembolism compared to control interventions (OR: 0.43,
95% CrI: 0.23–0.80). No clear difference between pharmacological thromboprophylaxis and
control was observed (OR: 0.93, 95% CrI: 0.19–4.37). On indirect assessment, no significant
difference between PCD and pharmacological therapy was found (OR: 0.47, 95% CrI: 0.09–
2.54). A similar pattern of findings was noted when data on any DVT/PE was assessed (S2 Fig).
CLOTS3 was the sole study to collect data on delays to treatment initiation. When stratified
by initiation time, patients started on PDCs within days 0–1 benefited to a statistically signifi-
cant degree (PCD: 7/74, 9.5% versus Control: 15/68, 22.1%; p<0.05), compared to patients
who started treatment on days 2–3 (PCD: 7/82, 8.5% versus Control: 14/90, 15.5%; p = 0.160).
A meta-analysis of hematoma expansion and mortality was dropped as data on these second-
ary outcomes were largely not reported.
Risk of bias across studies and strength of evidence
Two of the four randomized controlled trials were registered (CIREA1, CLOTS3). The out-
comes and study methodology outlined in the protocol match with the final manuscript. For
the remaining randomized controlled trials, the pre-determined outcome measures matched
with the final results reported.
Randomized trials formed the evidence base for both pharmacotherapy and PCD assess-
ments (S6 Table). Imprecision with inclusion of the null value resulted in the overall quality of
network meta-analysis to be considered “moderate” overall.
Discussion
While guidelines support the use of VTE prophylaxis in acute ICH, data around the relative
efficacy of management options are lacking [4,5,11,25,26]. In this systematic review, we used a
network meta-analysis to compare PCDs to pharmacological thromboprophylaxis.
The total event rate in our network was 9.9%, which is in keeping with previous studies of
symptomatic DVT rates in ICH varying from 3 to 7% [2,27]. In direct comparison, PCD were
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superior to control interventions. This comparison is supported by three high quality random-
ized controlled trials [22–24]. Each study assessed a mixed population of patients and as such,
we felt it prudent to contact study authors and seek out data on ICH patients, alone. The gen-
erated effect estimates are in keeping with a recently performed review [28], however, we
strengthened our assessment by acquiring ICH patient data from all three trials, thereby signif-
icantly reducing cohort and outcome heterogeneity.
Compression devices studies aimed to randomize patients within the 48–72 hours of symp-
tom onset, whereas pharmacotherapy was started only after the 48-hour mark. In CLOTS3,
45% of patients were randomized on day 0–1, while 55% were randomized on day 2–3. Our
post-hoc assessment of these sub-groups suggests that a delay in treatment reduces the overall
effectiveness of compression devices. It stands to reason that the potential risk of VTE may be
front-loaded. Analysis of the CLOTS 1 and 2 datasets reported the majority of DVT events
Fig 2. Network plots for pharmacotherapy (Pharma), pneumatic compression devices and venous thromboembolism. Each line connecting two nodes
indicates a direct comparison and the thickness of each line is proportional to the number of trials directly comparing the two modalities.
https://doi.org/10.1371/journal.pone.0234957.g002
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occurring in the first seven days from stroke onset [29]. In addition, an observational study of
pharmacotherapy by Boeer et al. [30] reported that the majority of VTE events were observed
at a day two ultrasound. This may partially explain the neutral results reported by Orken et al.
[21], where pharmacological agents were only introduced 48 hours after symptom onset. How-
ever, our comparative analysis is limited by the inclusion of only one study evaluating pharma-
cotherapy and the neutral findings observed may be secondary to a limited study sample.
Although we assessed a second randomized study performed by Dickmann et al. [31] for
potential inclusion in our primary analysis, a treatment start-time of four days post hemor-
rhage occurrence did not meet entry criteria based on our a priori protocol; this delay to treat-
ment start was not reflective of present practice in most institutions, or in line with practice
guidelines [4,5]. We also considered including observational studies, as was done by previous
reviews on pharmacotherapy [32], but issues with significant confounding and overall meth-
odology precluded us from doing so. Ultimately, meaningful conclusions regarding the effec-
tiveness, timing, or duration of anticoagulation cannot be made from the results of a single
study and randomized controlled trials are required to evaluate this further.
Additional limitations include a relative lack of reporting of safety data, mortality, and dis-
ability, with CLOTS3 being the sole study to provide a robust assessment of these measures.
The absence of this data reflects areas of must needed improvement and highlights the need
Fig 3. Network effect estimates forest plots for venous thromboembolism (Primary outcome). One direct comparison between pharmacotherapy and control. Three
direct comparisons between pneumatic compression devices and control. 607 patients included in the analysis with 60 recorded events.
https://doi.org/10.1371/journal.pone.0234957.g003
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for further investigations in pharmacological prophylaxis and the greater need for increased
safety data with either intervention.
Conclusions
Early initiation of PCD is associated with a lower odds of VTE in patients presenting acutely
with ICH when compared to control interventions. A relative lack of data around pharmaco-
therapy limits the conclusions we can make from our network meta-analysis and further ques-
tions should be explored via large pragmatic trials.
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